What question did this study set out to answer?

To evaluate the rates of multigene testing in post-operative cases of recurrent non-small-cell lung cancer (NSCLC) and its implications for patient prognosis.

April 4, 2026ESMO Open0 citationsOpen Access

View Full Paper

Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L

TMT. Matsubara TST. Sakamoto TTT. Takahama

Key Points

To evaluate the rates of multigene testing in post-operative cases of recurrent non-small-cell lung cancer (NSCLC) and its implications for patient prognosis.
Analyzed multigene testing rates in postoperative NSCLC patients
Evaluated the availability of surgical specimens
Assessed the role of personalized medicine in treatment outcomes
Low rates of multigene testing observed despite sufficient specimens
Indication that increased testing could improve patient outcomes
Emphasis on the need for broader adoption of personalized medicine approaches

Abstract

The rate of multigene testing in post-operative recurrent NSCLC cases was low despite the availability of sufficient surgical specimens. The further widespread adoption of multigene testing is one of the most critical challenges for improving resected patient outcomes along with recent advances in perioperative personalized medicine.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L

Key Points

Abstract

Cite This Study

Also Consider

Also Consider